FMO5 and COVID-19: Although in the absence of statistical significance, we found a higher occurrence of thrombotic events in patients with COVID-19 than with FLU, confirming that coagulopathy represents a crucial aspect of this condition, possibly driven by the activation of NADPH oxidase and by an excessive harmful pro-inflammatory response [28].